论文部分内容阅读
目的:探讨奥美拉唑、克拉霉素、铋剂短程三联治疗幽门螺旋杆菌 (Hp)感染患者的疗效和安全性。 方法 :将 Hp阳性的 183例病人随机分成治疗组 (奥美拉唑 +克拉霉素 +铋剂 )、对照组 (奥美拉唑 +甲硝唑 +铋剂 ) ,疗程 7d。溃疡患者继续服用奥美拉唑 2 0 mg,每日 1次 ,治疗至 1个月 ,复查胃镜 ,了解 Hp根除和溃疡愈合的情况。结果:治疗组及对照组对 Hp根除率分别为 89.0 %和 72 .8% ,消化道症状缓解率分别为 94.5 %和 82 .6 % ,溃疡愈合总有效率分别为 95 .8%和 85 .5 % ,副作用发生率分别为 6 .6 %和 19.6 % ,对照组治疗无效的病例继续采用治疗组治疗方案 ,其 Hp根除率可达 84.0 %。结论 :奥美拉唑、克拉霉素、铋剂三联短程疗法对根除 Hp及甲硝唑治疗无效的 Hp感染患者均有较好的作用
Objective: To investigate the curative effect and safety of omeprazole, clarithromycin and bismuth triple therapy in the treatment of patients with Helicobacter pylori (Hp) infection. Methods: 183 Hp positive patients were randomly divided into treatment group (omeprazole + clarithromycin + bismuth) and control group (omeprazole + metronidazole + bismuth) for 7 days. Obese patients continue to take omeprazole 20 mg once daily for 1 month, review the endoscopy to understand the eradication of Hp and ulcer healing. Results: The eradication rates of Hp in treatment group and control group were 89.0% and 72.8% respectively, and the remission rates of digestive tract symptoms were 94.5% and 82.6% respectively. The total effective rates of ulcer healing were 95.8% and 85% respectively. 5%. The incidence of side effects were respectively 6.6% and 19.6%. The patients in the control group treated with the treatment regimen continued to use the treatment group and the Hp eradication rate was 84.0%. Conclusion: Omeprazole, clarithromycin, bismuth triple short-term therapy have a good effect on Hp infection and eradication of Hp in patients with eradication of Hp infection